Intestinal ultrasound in ulcerative colitis – an objective biomarker for treatment response?

Johan F.K.F. Ilvemark, MD, PhD fellow.

Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

The use of transabdominal intestinal ultrasound (IUS) as an objective biomarker of inflammation in ulcerative colitis (UC) is gaining acceptance [1]. IUS ability to correctly identify inflammation and extent of inflammation has been explained in several studies [2]. The advantages over endoscopy or other cross-sectional modalities are many; IUS is a non-invasive, preparation – and radiation-free, easily repeated and patient friendly modality [1]. When visualizing disease burden in real-time, clinicians can better explain and motivate treatment decisions, helping patients to understand their disease [3].

Different IUS parameters of inflammation (increased bowel wall thickness (BWT), increased color doppler signals, disrupted bowel wall stratification, loss of haustration, presence of inflammatory mesenteric fat, ascites and mesenteric lymphadenopathy) has been shown to significantly improve/restore during treatment [4]. BWT is the most common and examined parameter [2]. In the largest UC follow-up study to date (n = 224), the percentage of patients with an increased BWT as baseline (sigmoid colon 89% and descending colon 83%), decreased significantly already within the first 2 weeks of treatment (sigmoid colon 38% and descending colon 43%). BWT remained low at week 6 and 12, with a high correlation with clinical response at week 12 [4]. It has therefore been suggested, that IUS could be an objective biomarker for treatment response in ulcerative colitis and a predictor of treatment outcome. Several studies are currently examining this hypothesis.

IUS might be proven especially useful in severe UC. Severe UC patients has a 34% risk of steroid treatment failure [6], which is associated with a higher mortality rate compared to steroid treatment responders (2.9–1.8% vs. 0.19–0.0% [7]. Early identification of treatment failure is therefore highly warranted. Smith et al. recently published a pilot study, consisting of 10 patients hospitalized with severe UC. A high BWT (median 6.2 mm compared to 4.6 mm) assessed within the first 24 hours of admission, was predictive of steroid treatment failure [5].

Our research group (Herlev, Hvidovre and Aarhus University Hospital, Denmark), has recently finished recruiting 60 hospitalized UC patients. Before intravenous steroid treatment, all patients underwent an IUS assessment (based on BWT, color doppler signals, disrupted bowel wall stratification, loss of haustration, and presence of inflammation).
Inflammatory mesenteric fat), followed by a follow-up scan at 48 ± 24 hours after treatment initiation. We hypothesize, that IUS can already detect treatment response within the first 48 ± 24 hours. Data is currently being analyzed.

In conclusion, the use of transabdominal intestinal ultrasound as an objective biomarker for treatment response in UC is gaining acceptance. Initial data are promising, while more studies are highly warranted.

References


